Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study (Q34647728)

3 August 2017

Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study (English)

1 reference

3 August 2017

0 references

1 reference

1 reference

coronary artery disease

1 reference

based on heuristic

inferred from title

author

Jean-Charles Fruchart

7

0 references

Jean Ferrières

4

object named as

Jean Ferrieres

1 reference

3 August 2017

Philippe Amouyel

6

0 references

Pierre Ducimetière

8

object named as

Pierre Ducimetiere

1 reference

3 August 2017

Gérald Luc

1

1 reference

3 August 2017

Jean-Marie Bard

2

1 reference

3 August 2017

Dominique Arveiler

3

1 reference

3 August 2017

Alun Evans

5

1 reference

3 August 2017

PRIME Study Group

9

1 reference

3 August 2017

1 August 2002

1 reference

3 August 2017

1 reference

3 August 2017

163

1 reference

3 August 2017

2

1 reference

3 August 2017

377-384

1 reference

Lipoprotein(a). A unique risk factor for atherothrombotic disease

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

Lipoprotein(a) as a risk factor for coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

Methodologic problems and standards in case-control research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

Lipoprotein(a) in stored plasma samples and the ravages of time. Why epidemiological studies might fail

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

The PRIME study: classical risk factors do not explain the severalfold differences in risk of coronary heart disease between France and Northern Ireland. Prospective Epidemiological Study of Myocardial Infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

Lipoprotein(a) and cholesterol levels act synergistically and apolipoprotein A-I is protective for the incidence of primary acute myocardial infarction in middle-aged males. An incident case-control study from Sweden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

Apolipoproteins and ischaemic heart disease: implications for screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

A prospective study of obesity, lipids, apolipoproteins and ischaemic heart disease in women

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

inferred from DOI database lookup

7 January 2021

based on heuristic

cDNA sequence of human apolipoprotein(a) is homologous to plasminogen

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

Prevalence of hypercholesterolemia among siblings of persons with premature coronary heart disease. Application of the Second Adult Treatment Panel guidelines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900026-6

10.1016/S0021-9150(02)00026-6

7 January 2021

Identifiers

DOI

1 reference

3 August 2017

1 reference